PRELUDE THERAPEUTICS INC Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
PRELUDE THERAPEUTICS INC (PRLD) reported Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes · last filed 2026-03-10
- PRELUDE THERAPEUTICS INC effective income tax rate reconciliation, state and local income taxes, amount for fiscal 2025 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |